A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma
Latest Information Update: 28 Dec 2023
At a glance
- Drugs Dacarbazine (Primary) ; Doxorubicin (Primary) ; Pembrolizumab (Primary) ; Vinblastine (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Results(n=50) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 27 Nov 2023 Planned primary completion date changed from 13 Apr 2024 to 21 Dec 2023.
- 02 May 2023 Planned primary completion date changed from 1 Dec 2024 to 13 Apr 2024.